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Hydrocortisone has long been the treatment of choice for congenital adrenal hyperplasia (CAH). However, treatment with this
medication remains problematic. Patients with 21-hydroxylase deficiency CAH have significant diurnal variation in the secretion
of 17-hydroxyprogesterone (17OHP). When considering treatment strategies, this variation must be considered along with the
pharmacokinetic and pharmacodynamic properties of exogenous glucocorticoids. Orally administered hydrocortisone is highly
bioavailable, but it has a short time to maximum concentration (Tmax) and half life (T1/2). While prednisone has a somewhat
longer Tmax and T1/2, they remain relatively short. There have been several studies of the pharmacodynamics of hydrocortisone.
We present data indicating that the maximum eﬀect of hydrocortisone in CAH patients is seen 3 hours after a morning dose. After
an evening dose, suppression of adrenal hormones continues until approximately 0500 the next day. In both situations, however,
there is a large degree of intersubject variability. These data are consistent with earlier published studies. Use of alternate specimen
types, possibly in conjunction with delayed release hydrocortisone preparations under development, may allow the practitioner
to design a medication regimen that provides improved control of androgen secretion. Whatever dosing strategy is used, clinical
judgment is required to ensure the best outcome.
1. Introduction
Glucocorticoids and mineralocorticoids are mainstays of the
treatment of individuals with congenital adrenal hyperplasia
(CAH). Several diﬀerent glucocorticoids are in common
use, including hydrocortisone, prednisone/prednisolone,
and dexamethasone. Each of these agents has diﬀerent phar-
macokinetic and pharmacodynamic properties, and tailoring
their dosing to provide individualized and appropriate con-
trol of adrenal androgen secretion remains a major clinical
challenge. In this article, we will review the secretory patterns
of adrenal steroids and discuss the pharmacokinetics of
hydrocortisone and prednisolone. We will then present data
from ourselves and others regarding the pharmacodynamics
of hydrocortisone and review principles of treatment relating
to steroid dosing.
2. Variability of Cortisol and
17-Hydroxyprogesterone (17OHP) Secretion
When assessing the eﬃcacy of CAH treatment with diﬀerent
doses of glucocorticoids, one must take into account normal
diurnal secretory patterns. It has long been known that
cortisol production rates range between 5–9 mg/m2/day. This
holds true for neonates, children, adolescents, and adults
[1, 2]. The serum concentration of cortisol in normal
individuals with typical sleep-wake patterns begins to rise
at about 0400 and reaches its peak between 0700 and
0900 [3]. Over time, this diurnal variation is constant
within individuals, although person-to-person variability
is large [4]. Similarly, the variation of 17OHP secretion
over a 24-hour period has long been recognized [5, 6].
Untreated subjects with CAH experience increasing serum
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concentrations of 17OHP between 2400 and 0400. After
1200, 17OHP levels spontaneously fall, although even at
their nadir they remain much higher than normal [7, 8].
In treated patients with CAH, a similar pattern is observed.
Charmandari et al. studied steroid secretory patterns in 36
treated children and adolescents with CAH [9]. They divided
the 24-hour day into two periods: daytime, defined as 0400–
1600, and nighttime, defined as 1600-0400. Mean 17OHP
levels for 19 individuals who were relatively unsuppressed
were 5296 ng/dL during the daytime and 2350 ng/dL during
the nighttime. In the 17 subjects who were more completely
suppressed, this diurnal variation was present but not as
apparent. In this group, daytime 17OHP concentrations
averaged 59 ng/dL, and nighttime concentrations averaged
36 ng/dL.
3. Pharmacokinetics of Commonly Used
Glucocorticoids
An understanding of the pharmacokinetics of hydrocorti-
sone and prednisone/prednisolone is helpful when planning
a treatment regimen for CAH, particularly in regards to
the timing of multiple doses and when adjusting doses to
improve control.
3.1. Hydrocortisone. Hydrocortisone is rapidly absorbed
after an oral dose, and concomitant food intake does not
appear to prevent absorption [10]. Hydrocortisone has a
high degree of intestinal permeability, crossing the intestinal
mucosa in a passive fashion. The bioavailability after oral
administration is high, >90% [11], and the time to peak
concentration (Tmax) is roughly 1-2 hours. However, this
depends on the exact formulation administered, because it
is thought that the rate dependent step in absorption is the
dissolution of hydrocortisone tablets [10]. The elimination
half-life (T1/2) of hydrocortisone is also short, 1.8–2 hours
following either oral or intravenous administration. The
pharmacokinetics of hydrocortisone are nonlinear, in part
due to extensive protein binding. As a result, higher doses
result in more rapid clearance rates [11]. Hence, doubling
the dose does not lead to doubling of the area under
the curve of plasma hydrocortisone versus time. A typical
pharmacokinetic profile of hydrocortisone is shown in
Figure 1.
3.2. Prednisone/Prednisolone. Similar to hydrocortisone,
prednisone is also rapidly and nearly completely absorbed
after an oral dose. However, prednisone itself is biologically
inactive, and before having any eﬀect, its 11-keto group
must be reduced by hepatic 11-β-hydroxysteroid dehydro-
genase to form the active drug, prednisolone. Although
this transformation occurs rapidly, it does account for
the delayed Tmax of prednisone versus prednisolone (2.6
hours versus 1.3 hours, resp.) [11]. There is bidirectional
interconversion of prednisone and prednisolone, with 76%
recycling, although the enzyme kinetics favor the formation
of prednisolone [13]. The T1/2 of both prednisone and




















Figure 1: Pharmacokinetic profile following the morning admin-
istration of intravenous and oral doses of hydrocortisone in 16
subjects with CAH, at a median age of 10.6 years. Figure taken from
[12]. Society for Endocrinology, 2001. Used with permission.
in children suggest that the T1/2 may be shorter, 2.2
hours [11, 14], possibly due to a more rapid clearance
rate [15]. The kinetics do not appear to be altered by
gastrointestinal disease or renal transplant status [16, 17],
but untreated hypothyroidism leads to a dramatic decrease
in clearance [18]. Prednisone/prednisolone has complex,
nonlinear pharmacokinetics due to protein binding which
becomes saturated at higher doses. This leads to increasing
clearance rates and a decrease in the peak concentration
achieved per milligram dose. However, this phenomenon
has been recognized at doses well above those used for
nonstressed CAH patients [11].
4. Pharmacodynamics of Commonly Used
Glucocorticoids
When used to treat CAH, both the pharmacokinetics and
pharmacodynamics of steroid preparations must be consid-
ered. Superimposed on the pharmacokinetics are the diurnal
variations in ACTH, cortisol, 17OHP, androstenedione, and
testosterone secretion. Thus, timing of administration of the
steroid relative to adrenal hormone secretion becomes a crit-
ical factor when interpreting subsequent levels. There have
been limited studies of the eﬀectiveness of hydrocortisone
administration at suppressing endogenous hormone concen-
trations in subjects with CAH [8, 9, 19, 20]. The studies have
been performed almost exclusively in individuals receiving
hydrocortisone treatment, with only a few subjects receiving
prednisone.
We studied 16 subjects (9 males) with 21-hydroxylase
deficiency CAH at a mean age of 12.2 ± 5 years who were
receiving hydrocortisone three times daily [19]. Institutional
review board approval and informed consent/assent were
obtained. After an overnight admission with their usual
evening hydrocortisone dose, subjects were administered
their usual morning dose of steroid after obtaining baseline
serum concentrations of 17OHP, androstenedione, and
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Figure 2: Serum concentrations of 17-hydroxyprogesterone, androstenedione, and testosterone after administration of hydrocortisone in
the morning. ∗P < .05 compared to baseline.
testosterone. Following steroid administration at times rang-
ing from 0700 to 0830, serial measurements of serum 17OHP
and androstenedione (hourly) and testosterone (every two
hours) were made. Baseline concentrations of 17OHP and
androstenedione were quite elevated at 12,657 ng/dL and
311 ng/dL, respectively. Maximum suppression of 17OHP
and androstenedione occurred 3 hours after administration
of steroid, and levels of both substances then began to return
gradually towards baseline (Figure 2). Seven hours after
administration of steroid, 17OHP concentrations remained
at 59% of baseline, while androstenedione concentrations
were at 62% of baseline. Serum testosterone concentrations
were also elevated at baseline and then appeared to decline
slightly, with a nadir three hours after steroid dosing, but this
did not reach statistical significance.
A similar study was conducted on a diﬀerent group of
six subjects to assess further the overnight suppression of
adrenal function. Subjects were given their usual evening
doses of hydrocortisone and then had serum concentrations
of androstenedione, 17OHP, and testosterone measured
every two hours from 2100 until 0900 the next morning.
(Figure 3) In the six subjects in whom androstenedione was
measured, concentrations were stable and relatively low until
0300. By 0500, androstenedione concentrations had begun
to increase steadily until the end of the study at 0900.
Five of the subjects had 17OHP and testosterone measured
according to the same protocol. 17OHP concentrations at
baseline averaged 665 ng/dL and declined to 324 ng/dL after
two hours. Levels stayed suppressed until 0500, when they
increased to 2625 ng/dL, and then continued to increase
steadily until 0900, at which time the study stopped.
Testosterone concentrations, by contrast, did not show a
significant decline after administration of hydrocortisone,
and they remained stable through the night and into the
morning. Although there are clear trends in the patterns of
overnight secretion, most of the data were not statistically
diﬀerent because of the small number of subjects.
During both the daytime and overnight studies, there
was a large degree of variability among subjects for all
three hormones, both at baseline and during the monitoring













































































































































































Figure 3: Serum concentrations of 17-hydroxyprogesterone, androstenedione, and testosterone after administration of a nighttime dose of
hydrocortisone. ∗P = .05 compared to baseline.
periods. This is similar to the variability noted in other
studies [8, 9, 20].
Thus, after administration of steroid to subjects with
CAH at night, when hypothalamic-pituitary-adrenal (HPA)
axis activity is relatively low, subjects maintained 17OHP and
androstenedione levels in a low, stable range for approxi-
mately eight hours, until 0500. In contrast, administration
of steroid in the morning, during peak HPA axis activity,
resulted in a short-lived suppression of adrenal activity
lasting only three hours. Thus, the timing of measurement
of 17OHP relative to the 24-hour clock and the timing
relative to dosing of glucocorticoid are both critical for the
interpretation of pharmacodynamic data.
There have been several previous reports of the phar-
macodynamics of hydrocortisone use in patients with CAH.
In an older study, Frisch et al. [8] studied 11 prepubertal
and pubertal children, seven of whom were receiving hydro-
cortisone. Subjects had a rapid suppression of 17OHP after
the morning dose and a mid-day dose 5 hours later. They
received an evening dose at 1830, and 17OHP concentrations
began to rise between 2400 and 0200. Testosterone concen-
trations remained suppressed during the day, but increased
in most subjects after 0200. Thus, their results diﬀered from
ours in that the rise in HPA axis activity seemed to occur
earlier and testosterone levels showed a diurnal variation.
Charmandari et al. [9] studied 36 prepubertal and
pubertal subjects with CAH, all of whom were receiving
hydrocortisone. They obtained samples at 20 minute inter-
vals over a 24-hour time period. Morning administration
of hydrocortisone also resulted in a rapid drop of 17OHP
concentrations, with maximum suppression occurring one
hour after peak cortisol levels were attained. The majority
of their subjects received hydrocortisone twice daily, with
only 39% receiving it in three divided doses. Mean serum
17OHP concentrations during the day were stable in the
total group and declined further after the evening dose
of hydrocortisone at 2100–2200. In their subjects, 17OHP
began to rise again at 0400. Hence, their data are consistent
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with ours regarding the time course of suppression in the
morning and escape overnight. They did not compare the
twice-daily hydrocortisone group to the three-times-daily
group.
In a study of the salivary secretion of cortisol and 17OHP,
Gro¨schl et al. [20] evaluated 10 normal adult controls
and 10 children with CAH and found that hydrocortisone
administered at 0700 led to a rapid reduction in salivary
17OHP levels, reaching a nadir at three hours. Thereafter,
levels of 17OHP began to increase steadily, although they
remained below baseline at five hours. They also noted
significant variability in response to hydrocortisone among
subjects. Again, these data are similar to ours. These authors
also noted a more rapid clearance of hydrocortisone from
salivary samples in aﬀected subjects (T1/2 = 56.4 minutes)
compared to normal controls (T1/2 = 94.5 minutes).
There have been limited studies of the pharmacodynam-
ics of prednisone use in individuals with CAH. Huseman
et al. evaluated the ability of prednisone to control CAH
when administered at diﬀerent frequencies. It appeared that
when a single daily dose of prednisone was administered
at 2000 hours, the 17OHP concentration had escaped from
suppression by 0900 the next morning in four of their six
subjects. Unfortunately, they did not measure 17OHP levels
at any other times, so the duration of action could not be
evaluated further [21]. In a study by Zipf et al., a group of six
subjects who were being treated with prednisone had hourly
measurements of serum 17OHP concentrations [22]. Five of
the six subject did not demonstrate escape from suppression.
All of the subjects were either quite short or had short adult
heights, suggesting that they were being chronically over
treated. The subject who did escape suppression appeared
to do so at about 0500, following a midnight dose of
prednisone. Four subjects reported by Frisch et al. [8],
appeared to escape suppression between 2400 and 0500 after
an 1800 dose of prednisone given the day before. We studied
four subjects receiving prednisone who were not included
in the above analysis, and based on these very limited data,
there was no diﬀerence from those receiving hydrocortisone,
although any diﬀerences may be diﬃcult to identify given the
high subject-to-subject variability.
5. Methods Used to Assess Control of CAH
The degree of suppression of adrenal metabolites is most
often assessed by measuring the concentrations of 17OHP,
androstenedione, and/or testosterone. These substances are
most commonly measured in serum, but 17OHP has also
been measured in filter paper blood spots and in saliva.
Historically, studies have used radioimmunoassays (RIAs),
but high performance liquid chromatography-tandem mass
spectrometry techniques (HPLC-MSMS) have more recently
been applied to the measurement of these analytes. HPLC-
MSMS oﬀers the advantage of significant increases in the
specificity of the assay, which may be relatively low in
some RIAs, particularly if performed in the newborn period.
Because of the increased assay specificity, concentrations of
these substances may be reported as lower when measured by
HPLC-MSMS than by RIA. This makes it diﬃcult to compare
recent data using modern assay techniques to older data,
especially those using less specific polyclonal RIAs.
Data from filter paper blood spots show good corre-
lation with results obtained simultaneously from serum,
with serum levels generally corresponding to those from
filter paper spots. Additionally, there appears to be little
degradation related to storage time or temperature over a
two-week period [23, 24].
17OHP is present in saliva in concentrations far lower
than in serum. Older techniques to measure salivary 17OHP
used RIAs that were initially developed for use with serum
and subsequently modified to use with saliva [20, 25]. Newer
techniques have taken advantage of the higher specificity of
HPLC-MSMS to measure 17OHP in saliva [26]. Correlation
between serum and salivary 17OHP using modified RIAs
is variable (r = 0.62–0.93), [25, 27] while the correlation
using HPLC-MSMS appears to be higher (r = 0.98), [26]
likely related to increased specificity. Additionally, 17OHP
concentrations in saliva were 3-4% of those in serum using
the modified RIAs, but only 0.5% when the HPLC-MSMS
technique was employed. This again probably reflects the
increased specificity of mass spectrometry.
6. Optimizing the Dosing Schedule for CAH
Despite the availability of longer acting glucocorticoids such
as prednisone and dexamethasone, hydrocortisone remains
the drug of choice for treatment of children with CAH
according to the position statement by the Lawson Wilkins
Pediatric Endocrine Society and the European Society for
Pediatric Endocrinology [28] and the forthcoming clinical
practice guideline from The Endocrine Society. This is
because of the higher potential for growth suppression
with longer acting, more potent steroids [28, 29]. Recom-
mendations for dosing vary, but current data suggest that
the daily dose of hydrocortisone during puberty should
be kept below 17 mg/m2 if possible, in order to minimize
its growth suppressive eﬀects [30]. Unfortunately, the rel-
atively short half life of hydrocortisone leads to diﬃculties
suppressing adrenal androgen production, particularly early
in the morning as seen in the data presented above [31].
This has led to diﬀerent opinions regarding how best to
approach the administration of hydrocortisone. As discussed
above, 17OHP and androstenedione reach their highest
concentrations in serum early in the morning, and some
authors have recommended administering hydrocortisone in
split doses with the largest share given early in the morning
[9]. While this will lead to rapid suppression of the high
17OHP and androstenedione levels, it does not address the
increasing concentrations of adrenal hormones that begins
at about 0400. Others have recommended giving a larger
dose of hydrocortisone at bedtime, with the expectation that
this dose will suppress, at least partially, the early AM surge
[32, 33]. The eﬀectiveness of this is uncertain given the
short T1/2 of hydrocortisone and the need for relatively high
concentrations of cortisol to suppress endogenous steroid
production in the early morning. Additionally, circulating
levels of cortisol overnight are normally quite low, and in
patients with CAH much less hydrocortisone is required
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to suppress adrenal steroid production in the timeframe of
2200–0200. Giving a large hydrocortisone dose at bedtime
thus potentially exposes the patient to unnecessarily high
levels during this window. At the present time, there is no
consensus on this point, and practice guidelines and position
statements do not recommend specific dosing strategies to
address this.
In attempts to tailor hydrocortisone administration to
the specific needs of patients with CAH, sustained release
preparations have been developed. Two recent publications
have presented data on these preparations. Johannsson et al.
[10] studied a dual release hydrocortisone tablet that had
a rapidly released coating surrounding a sustained release
core. Using this preparation once daily in the morning,
they were able to duplicate peak cortisol concentrations
with gradually declining levels during the day and very low
concentrations overnight. However, this preparation did not
duplicate the early morning increase in cortisol between 0400
and the time of medication administration. While this profile
may be suited to patients with adrenal insuﬃciency, it may
not be optimal for those with CAH, as adrenal metabolite
production would already be near its peak when the dose
is given. Debono et al. [34] studied a diﬀerent sustained
release hydrocortisone preparation which had a time to peak
concentration in healthy subjects of 7-8 hours, compared to
1.8 hours for standard hydrocortisone tablets. This allowed
for a three-hour lag after administration before the serum
concentration of cortisol began to increase. Using these
data for varying doses of the sustained release preparation,
they simulated administering a dose at 2300 and another
dose at 0700. This resulted in a pattern that mimicked
the normal diurnal variation of cortisol concentration, with
serum cortisol levels being low from 2300 to 0300, increasing
to reach a peak level at 0700, and then gradually declining
back to baseline. This medication has not been studied
in subjects with CAH, but it oﬀers promise for a tailored
therapy that potentially could improve control and reduce
the incidence of long-term growth complications of the
condition and its treatment.
There has been limited experience in the delivery of
hydrocortisone by continuous subcutaneous infusion using
an insulin pump, but this is also has the potential for
fitting the administration of hydrocortisone to physiologic
requirements for those with CAH [35, 36]. One of the
authors (DR) has achieved excellent control of adrenal
steroid precursors without apparent deleterious eﬀects on
growth by administering a small dose of prednisone in the
evening to provide longer-term overnight and early morning
suppression and then giving hydrocortisone during the day
to suppress daytime adrenal hormones.
It has long been known that there is a spectrum of
salt loss in those with CAH, including those who clinically
have the simple virilizing form. These individuals may have
elevated levels of plasma renin activity despite normal elec-
trolyte concentrations, indicating subclinical hypovolemia.
Treatment of these patients with mineralocorticoid reduces
the hypovolemic drive for ACTH secretion and can lower the
amount of glucocorticoid needed to appropriately suppress
adrenal function. This was demonstrated in 1977 by Rosler
et al., who found that treatment of nonsalt wasting patients
normalized ACTH secretion and led to further suppression
of adrenal steroid secretion [37]. In a later study, Jansen
et al. demonstrated that institution of mineralocorticoid
therapy in five subjects with CAH allowed for a decrease
in the mean dose of hydrocortisone from 26 mg/m2/day to
17.6 mg/m2/day and resulted in improved linear growth [38].
In a retrospective study of the influences of CAH treatment
on adult height, patients treated with mineralocorticoid were
taller than untreated patients with similar disease severities
[39]. Thus, consideration should be given to treating both
the salt wasting and simple virilizing forms of CAH with 9α-
fludrocortisone.
7. Measuring Control of CAH
Similar to the diﬀerent dosing strategies for hydrocortisone,
there are diﬀerent strategies for monitoring the adequacy
of control. First and foremost, clinical judgment must be
used. This encompasses assessments of height velocity, status
of pubertal development, weight gain, skeletal maturation,
and adherence to the medication regimen. Any biochemical
assessments must be considered in their clinical context. Typ-
ically, serum concentrations of 17-hydroxyprogestereone,
androstenedione, and testosterone are used as an aid to judge
the adequacy of biochemical control. In prepubertal children
and in adolescent and adult females, androstenedione and
testosterone concentrations are thought to correlate better
with adrenal suppression than 17OHP levels. In pubertal
males, testosterone levels are not helpful. [40] Laboratory
studies may be obtained as a first morning sample or as
a random sample at the time of the patient’s follow-up
appointment. Although the latter strategy oﬀers convenience
for the patient and physician, the sample may be obtained at
diﬀerent times relative to the last steroid dose and at diﬀerent
times of the day, resulting in inconsistent assessments of
the degree of suppression. For this reason, it is often rec-
ommended that biochemical measurements be done in the
morning, with consistent timing relative to the last steroid
dose [28, 32, 41]. In either case, the time of administration
of the previous steroid dose should be noted and taken
into consideration when interpreting the results. Additional
approaches mentioned above include at-home collection of
filter paper blood spots or saliva. These strategies oﬀer the
advantage of being able to collect multiple specimens at
diﬀerent times of day, both before and after steroid dosing
[23, 24]. They potentially allow for individual titration of
each dose of steroid, again with the goal of giving the amount
needed to adequately suppress adrenal function, but not to
overly suppress it. A strategy such as this would also enable
the physician to adjust the steroid dose to allow for the person
to person variation in glucocorticoid clearance rates and
individual pharmacodynamics. Unfortunately, assays of 17-
hydroxyprogesterone and androstenedione in saliva are not
widely available in the U.S. Although newborn screening for
CAH using filter paper blood spots is performed universally
in the U.S., this technology is also not currently commercially
available for routine follow-up studies of patients already
diagnosed with CAH.
International Journal of Pediatric Endocrinology 7
8. Conclusions
In summary, hydrocortisone is the glucocorticoid usually
recommended for the treatment of children with CAH.
Its rapid onset of action makes it useful for the rapid
suppression of adrenal androgen secretion, but its relatively
short half life allows for escape from suppression, particularly
in the early morning after nighttime administration. Data
show that 17OHP and androstenedione concentrations
begin to rise at 0300–0500 when hydrocortisone is given
at 2100–2200. Morning administration of hydrocortisone
results in rapid suppression of 17OHP and androstene-
dione, but because of high morning HPA axis activity,
escape occurs after 3-4 hours, requiring a mid-day dose
to maintain suppression. Measurement of serum 17OHP
and androstenedione concentrations 3-4 hours after the
morning dose of hydrocortisone will demonstrate maximal
adrenal suppression. Measurement of adrenal hormones in
saliva or in dried filter paper blood spots would allow a
more complete profile of CAH control, and we encourage
the commercial development of these approaches. Although
prednisone/prednisolone has a longer half life, its pharmaco-
dynamics have not been well studied in children with CAH.
Hydrocortisone dosing recommendations include admi-
nistering the largest dose in the evening or in the morning,
but neither one is likely to provide optimum control. Giving
the evening dose of hydrocortisone as late as possible and the
morning dose as early as possible, with a mid-day dose 4-5
hours after the morning dose may oﬀer the best compromise.
Sustained or delayed release hydrocortisone preparations
are in development and oﬀer promise for CAH patients.
The combination of diﬀerent glucocorticoid preparations
with diﬀerent pharmacologic profiles merits further study,
analogous to the approach used to treat diabetics with
multiple insulin preparations.
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